Participation of factor B in residual immune complex red cell binding activity observed in serum from a C2-deficient systemic lupus erythematosus patient may delay the appearance of clinical symptoms

2.50
Hdl Handle:
http://hdl.handle.net/2336/49715
Title:
Participation of factor B in residual immune complex red cell binding activity observed in serum from a C2-deficient systemic lupus erythematosus patient may delay the appearance of clinical symptoms
Authors:
Traustadottir, K H; Rafnar, B O; Steinsson, K; Valdimarsson, H; Erlendsson, K
Citation:
Arthritis Rheum. 1998, 41(3):427-34
Issue Date:
1-Mar-1998
Abstract:
OBJECTIVE: To investigate whether participation of factor B (FB) in immune complex transport might explain long periods of clinical remissions in a homozygous C2-deficient patient with systemic lupus erythematosus (SLE) treated regularly with plasma infusions. METHODS: Immune complex red cell binding (ICRB) was assayed as enzyme activity, C3d by enzyme-linked immunosorbent assay, and FB by immunoelectrophoresis. RESULTS: C2-deficient sera showed low-grade ICRB, which correlated with levels of FB. This activity could be blocked with antibodies to C1q, C4, or FB, but not by antibodies to C2. C3d levels in the patient's plasma changed during infusion, followed by a gradient increase during remission. Comparison of ICRB, C3d, and FB suggested an inverse relationship between FB levels and clinical symptoms. CONCLUSION: In C2 deficiency, FB may interact with C4 to provide a low-grade ICRB. This activity could be clinically significant in patients with C2 deficiency and explain why they are less prone to SLE than patients with C1q or C4 deficiency.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1002/1529-0131(199803)41:3<427::AID-ART8>3.0.CO;2-7

Full metadata record

DC FieldValue Language
dc.contributor.authorTraustadottir, K H-
dc.contributor.authorRafnar, B O-
dc.contributor.authorSteinsson, K-
dc.contributor.authorValdimarsson, H-
dc.contributor.authorErlendsson, K-
dc.date.accessioned2009-02-20T13:51:37Z-
dc.date.available2009-02-20T13:51:37Z-
dc.date.issued1998-03-01-
dc.date.submitted2009-02-20-
dc.identifier.citationArthritis Rheum. 1998, 41(3):427-34en
dc.identifier.issn0004-3591-
dc.identifier.pmid9506570-
dc.identifier.doi10.1002/1529-0131(199803)41:3<427::AID-ART8>3.0.CO;2-7-
dc.identifier.urihttp://hdl.handle.net/2336/49715-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractOBJECTIVE: To investigate whether participation of factor B (FB) in immune complex transport might explain long periods of clinical remissions in a homozygous C2-deficient patient with systemic lupus erythematosus (SLE) treated regularly with plasma infusions. METHODS: Immune complex red cell binding (ICRB) was assayed as enzyme activity, C3d by enzyme-linked immunosorbent assay, and FB by immunoelectrophoresis. RESULTS: C2-deficient sera showed low-grade ICRB, which correlated with levels of FB. This activity could be blocked with antibodies to C1q, C4, or FB, but not by antibodies to C2. C3d levels in the patient's plasma changed during infusion, followed by a gradient increase during remission. Comparison of ICRB, C3d, and FB suggested an inverse relationship between FB levels and clinical symptoms. CONCLUSION: In C2 deficiency, FB may interact with C4 to provide a low-grade ICRB. This activity could be clinically significant in patients with C2 deficiency and explain why they are less prone to SLE than patients with C1q or C4 deficiency.en
dc.language.isoenen
dc.publisherWiley-Liss, Inc.en
dc.relation.urlhttp://dx.doi.org/10.1002/1529-0131(199803)41:3<427::AID-ART8>3.0.CO;2-7en
dc.subject.meshAntibodiesen
dc.subject.meshAntigen-Antibody Complexen
dc.subject.meshComplement C1qen
dc.subject.meshComplement C2en
dc.subject.meshComplement C4en
dc.subject.meshComplement Factor Ben
dc.subject.meshErythrocytesen
dc.subject.meshHumansen
dc.subject.meshLupus Erythematosus, Systemicen
dc.subject.meshTime Factorsen
dc.titleParticipation of factor B in residual immune complex red cell binding activity observed in serum from a C2-deficient systemic lupus erythematosus patient may delay the appearance of clinical symptomsen
dc.typeArticleen
dc.contributor.departmentThe National University Hospital, Landspítalinn, Reykjavik, Iceland.en
dc.identifier.journalArthritis and rheumatismen
All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.